Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
According to new survey data, nonadherence is not for lack of concern about the disease—75% of the women surveyed reported being concerned about their breast health.
Currently, there is no standardized reporting requirement related to BACs, and ACR classifies reporting vascular calcifications on breast imaging as optional.
Digital breast tomosythesis now makes up close to 50% of mammography systems in the U.S. "Tomo is going to replace just straight digital mammography simply because of the benefit of fewer recalls," explained Debra L. Monticciolo, MD.
Personalized breast cancer screening programs could help women better understand their personal cancer risks and guide providers in recommending mammographic assessments based on these risks.
Brian Lindman, MD, medical director of the Structural Heart and Valve Center, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program to screen with echo to find more AS patients.
Experts are calling for strategies to improve follow-up adherence among individuals who have positive lung cancer screenings after a new analysis revealed low rates of compliance.
A new paper highlights several studies supporting the use of screening mammography for women with breast implants, as well as additional considerations that need to be made for these patients.
Suggesting that the standard 10-year age gap screening rule might not be as beneficial as previously assumed, researchers have indicated that women with relatives diagnosed at younger ages should consider different screening criteria.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.